Background: During the past decade, several clinical trials investigating the potential benefits of homocysteinelowering therapy for the secondary prevention of vascular events were completed and published. The objective of the study was to determine trends in clinical laboratory testing for homocysteine at a single institution over the time period from 1997 to 2010. Subgroup analysis suggested that homocysteine testing for the indication of suspected nutritional deficiency or hypercoagulability remained steady despite a decline in testing for the indication of cardiac risk assessment. Conclusions: The frequency of clinical laboratory testing for plasma or serum homocysteine changed bimodally over the time period from 1997 to 2010. These observations suggest that clinical practice was impacted by emerging evidence from association studies and intervention trials investigating homocysteine as a potentially treatable cardiac risk factor.
Introduction
Homocysteine is a naturally occurring amino acid that is found in micromolar concentrations in blood plasma. Measurement of total homocysteine [ 1 ] in plasma or serum is often performed in the clinical laboratory to aid in the diagnosis of vitamin B12 deficiency or an inherited disorder of folate or vitamin B12 metabolism [ 2 ] . Clinical laboratory methods to accurately measure plasma or serum homocysteine became increasingly available in the 1980s and 1990s. During the same time period, several retrospective case control and observational studies demonstrated an association between elevated homocysteine levels and increased risk for coronary heart disease and stroke [ 3 , 4 ] . Elevated homocysteine was also found to be associated with an increased risk for deep vein thrombosis [ 5 , 6 ] . Results from these retrospective studies were confirmed by several large prospective cohort studies that evaluated risk for vascular events in subjects with elevated plasma homocysteine [ 7 , 8 ] . By the year 2000, there was growing awareness among clinicians that homocysteine may be a clinically relevant, independent risk factor for cardiovascular and thrombotic disease.
Beginning in the late 1990s and continuing into the early 2000s, several large, prospective, randomized clinical trials were initiated to define the potential benefits of homocysteine-lowering therapy for the secondary prevention of adverse vascular outcomes. These trials assessed the effects of supplementation with folic acid and other B vitamins on plasma homocysteine concentration and subsequent vascular outcomes in patients with a history of kidney disease or a prior vascular event, such as myocardial infarction, ischemic stroke, or venous thromboembolism. All of the intervention trials showed a significant reduction in plasma homocysteine concentration in subjects receiving supplemental B vitamins. However, none of the trials demonstrated a significant overall clinical benefit of homocysteine-lowering therapy for the secondary prevention of vascular events [ 9 -11 ] .
The result of the first major homocysteine-lowering intervention study, the VISP (Vitamin Intervention for Stroke Prevention) trial, was published in 2004. This trial failed to demonstrate that lowering homocysteine through B vitamin supplementation decreased the incidence of recurrent ischemic stroke [ 12 ] . The results of two additional intervention trials, the Heart Outcomes Prevention Evaluation 2 (HOPE-2) trial [ 13 ] and the Norwegian Vitamin Trial (NORVIT) [ 14 ] were published in 2006. In HOPE-2, supplementation with B vitamins lowered homocysteine but did not decrease the primary endpoint of combined risk of death from cardiovascular disease, myocardial infarction or stroke [ 13 ] . Similarly, NORVIT failed to demonstrate a benefit of homocysteine-lowering therapy for the prevention of recurrent myocardial infarction, stroke, or sudden death attributed to coronary artery disease [ 14 ] .
To assess the impact of the homocysteine-lowering intervention trials on clinical and laboratory practice, we performed a retrospective analysis to determine trends in clinical laboratory testing for plasma or serum homocysteine over the time period from 1997 to 2010 at a single academic tertiary care medical center in the USA.
Materials and methods
This study was conducted at the University of Iowa Hospitals and Clinics, a 760-bed teaching hospital and tertiary care medical center in Iowa City, Iowa. A Structured Query Language algorithm was used to search the patient information database for all occurrences in which plasma or serum total homocysteine [ 1 ] concentration was ordered between January 1, 1997 and December 31, 2010. For each occurrence, the associated date, laboratory value, patient identifi er, ordering provider, laboratory identifi er, and laboratory result were retrieved. Individual medical record reviews were performed on the subset of unique patients in the 10-year period between January 1, 2001 and December 31, 2010 who had homocysteine levels ≥20 μ mol/L (n = 221). Information retrieved from the medical record included the ordering provider ' s specialty, the clinical indication for the measurement, and the fi nal diagnosis, if available. The study protocol was reviewed and approved by the University of Iowa Institutional Review Board.
Results
From 1997 ( Figure 2 ) . Thirty-four patients had severe hyperhomocysteinemia, with a serum or plasma homocysteine level ≥50 μ mol/L. Of the patients with severe hyperhomocysteinemia, 24 had a documented nutritional deficiency (including deficiencies of B12, vitamin B6, and/or folate), six had chronic kidney disease, four had alcoholism, three had inborn errors of vitamin B12 metabolism (cobalamin C deficiency, cobalamin G deficiency, and homozygous MTHFR deficiency) and two had no identifiable etiology for hyperhomocysteinemia. Four patients had both chronic kidney disease and a nutritional deficiency and one patient had both alcoholism and a nutritional deficiency.
For the subset of 221 unique patients in this 10-year period who were found to have homocysteine levels of 20 μ mol/L or greater, the medical records were reviewed to determine the ordering provider ' s medical specialty and the clinical indication for requesting the homocysteine measurement. For most patients, the clinical indication for measuring homocysteine fell into one of three general categories: 1) assessment of cardiac risk; 2) hypercoagulability evaluation; or 3) suspected vitamin B12 deficiency ( Table 1 ) . Patients in the latter category often presented with either a hematological abnormality (including anemia with or without megaloblastic change, thrombocytopenia, leukopenia, and pancytopenia) or a neurological abnormality (such as altered mental status, cognitive impairment, peripheral neuropathies, ataxia, diplopia, nystagmus, optic nerve atrophy, weakness, or dizziness). Others were considered nutritionally " high risk " because of a known history of vitamin B12 deficiency or decreased nutritional intake, cachexia, alcoholism, or other conditions associated with malabsorption. Homocysteine laboratory testing was ordered for the indication of cardiac risk assessment most often by cardiologists, lipid specialists, or nephrologists. In contrast, homocysteine testing was requested for the indication of hypercoagulability evaluation or suspected nutritional deficiency most often by primary care providers (i.e., family medicine physicians, internists, pediatricians, or gynecologists), hematologists, neurologists or psychiatrists ( Table 1 ) 
Discussion
The major finding from this single-institution retrospective study is that the frequency of clinical laboratory testing for plasma or serum homocysteine changed bimodally over the time period from 1997 to 2001. The marked 16-fold increase in homocysteine testing from 1997 to 2003 likely reflects budding awareness by clinicians of homocysteine as a risk factor for cardiovascular disease due to the publication of several retrospective and prospective association studies in the late 1990s [ 7 , 8 ] . The subsequent decline in homocysteine testing corresponded with the publication of the negative results of the VISP study in 2004 [ 12 ] and the HOPE-2 and NORVIT trials in 2006 [ 13 , 14 ] . These observations suggest that clinical practice at this institution was impacted by emerging evidence from association studies and intervention trials investigating homocysteine as a potentially treatable cardiac risk factor. Limitations of this study include its retrospective design, the relatively small sample size, and the fact that the data reflect clinical practice at a single US institution. Due to these limitations, it is not possible to generalize the findings to other institutions or practice settings, especially outside of USA. Nevertheless, the patterns of utilization of clinical laboratory homocysteine testing observed in this study illustrate how emerging evidence may have impacted clinical practice at one institution and highlight potential areas of practice improvement for the future.
In patients ultimately found to have a homocysteine level ≥20 μ mol/L, we found that the medical indication for ordering a laboratory test for homocysteine varied between different medical specialists ( Table 1 ) . Cardiologists, lipid specialists and nephrologists accounted for almost all of the requests for homocysteine testing for the indication of cardiac risk stratification; moreover, these specialists ordered laboratory testing for homocysteine almost exclusively for this indication. In contrast, primary care providers requested homocysteine testing frequently for the indication of suspected vitamin deficiency and occasionally as part of a hypercoagulability evaluation, but almost never for the indication of cardiac risk stratification ( Table 1 ). This may reflect practice patterns at a US academic tertiary care center, where many patients with cardiac disease are cared for by cardiologists rather than primary care providers. Alternatively, primary care providers may have been slower than cardiologists to adopt the practice of utilizing homocysteine testing for cardiac risk assessment when homocysteine became recognized as an independent risk factor in the 1990s. Interestingly, the 10-year pattern of homocysteine testing for the indication of cardiac risk assessment in this patient subset ( Figure 3 A) mirrored the overall trends for the entire patient population ( Figure 1 ).
Among hematologists, the indications for ordering homocysteine were split between hypercoagulability evaluation and evaluation of hematologic abnormalities potentially attributable to B12 deficiency. Neurologists and psychiatrists ordered homocysteine testing mostly for evaluation of neurologic symptoms that were potentially attributable to B12 deficiency (such as ataxia, cognitive impairment, altered mental status, neuropathies, dizziness, diplopia, or nystagmus) and occasionally for hypercoagulability evaluation in the context of ischemic stroke. Other specialists who requested homocysteine testing include gastroenterologists, who tended to order testing for the indication of suspected nutritional deficiency in the setting of gastric bypass, chronic diarrhea, or proton-pump inhibitor use, and ophthalmologists, who ordered testing for the indication of hypercoagulability evaluation in the context of central retinal vein occlusion.
The pattern of homocysteine testing for evaluation of suspected nutritional deficiency has remained steady, or perhaps increased, after the publication of the negative results of the homocysteine-lowering intervention trials ( Figures 1 and 3B ) . The use of homocysteine testing, along with testing for methylmalonic acid and holotranscobalamin II, may continue to increase in the future as clinicians become more aware of populations at risk for vitamin B12 deficiency, including (often elderly) patients with malabsorption, alcoholism, inflammatory bowel disease, or conditions requiring long-term gastric acid-suppression therapy [ 15 , 16 ] .
